Analyst consensus rating
Adaptive Biotechnologies Analyst Rating: Strong Buy
Direct answer
Adaptive Biotechnologies's consensus rating is Strong Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $30.21.
Forecast evidence checked November 3, 2026.
Get free Adaptive Biotechnologies email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $25.06
- Average price target
- $30.21
- High price target
- $35.00
- Low price target
- $21.00
- Low target gap
- -16.2%
- Target upside
- +20.6%
- High target gap
- +39.7%
- Target range width
- 55.9%
- Consensus rating
- Strong Buy
- Analysts
- 7
- Evidence date
- November 3, 2026
- Valid through
- November 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Adaptive Biotechnologies?
Adaptive Biotechnologies has a verified Strong Buy consensus. The same dataset has an average price target of $30.21.
How far are Adaptive Biotechnologies's low and high targets from the recorded price?
The low target implies -16.2%, while the high target implies +39.7%.
How many analysts are included in Adaptive Biotechnologies's consensus?
The verified consensus includes 7 analysts.
How is Adaptive Biotechnologies's target upside or downside calculated?
The average target of $30.21 is divided by the recorded price of $25.06, then one is subtracted to produce +20.6%. This does not guarantee a future return.
When was Adaptive Biotechnologies's analyst forecast verified?
The data was verified on 2026-11-03. The dataset is valid through 2026-11-10.